William Tatum, DO
Epilepsy · Jacksonville, FLNPI 1396764122
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,202 of the $27,928 with a category attached, or 79.5%. Neurelis, Inc. accounts for 84.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $13,207 and has fallen 76.6% since, to $3,087 in 2025.
Across 40 payments — averaging $698.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$23K
- Medtronic$1K
- Zimmer Biomet$1K
- Natus Medical Incorporated$1K
- Livanova USA, Inc.$417
- Cadwell Industries, Inc$156
- plus $276 from 2 others
Across 62 payments — averaging $8804.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$227K
- UCB SA$181K
- Eisai Inc.$85K
- AbbVie$45K
- Medtronic$8K
What the payments were for
- Consulting fees$22,20279%
- Speaking & faculty fees$2,69210%
- Travel & lodging$9183%
- Food & beverage$2,1168%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 28 | $23,489 |
| Medtronic(2 entities) | 3 | $1,484 |
| Zimmer Biomet | 4 | $1,106 |
| Natus Medical Incorporated | 1 | $1,000 |
| Livanova USA, Inc. | 1 | $417 |
| Cadwell Industries, Inc | 1 | $156 |
| Neuropace, Inc. | 1 | $147 |
| SK Life Science, Inc. | 1 | $129 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$22,925
- ACTIVA$1,275
- ROSA$936
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$417
- RNS Neurostimulator Kit$147
- ACTIVA PC$122
How this compares
$27,928 in reported general payments places this provider in the 70th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 57 | $127,443 |
| BriviactBrivaracetam | 26 | $55,923 |
| EpidiolexCannabidiol (Cbd) | 15 | $44,780 |
| AptiomEslicarbazepine Acetate | 22 | $41,913 |
| NayzilamMidazolam | 34 | $31,224 |
| LamictalLamotrigine | 16 | $23,954 |
| ValtocoDiazepam | 13 | $16,841 |
| Clobazam | 52 | $14,570 |
| Lacosamide | 56 | $13,951 |
| NeurontinGabapentin | 12 | $7,678 |
| Lamotrigine ErLamotrigine | 23 | $4,137 |
| Lamotrigine | 72 | $1,825 |
| Levetiracetam | 50 | $1,701 |
| Levetiracetam ErLevetiracetam | 17 | $1,371 |
| Pregabalin | 15 | $944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $129 | $127,44357 claims |
| Neurelis, Inc.Valtoco | $23,489 | $16,84113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 23 epilepsy providers in Florida.
Other epilepsy in Jacksonville
- Brin FreundJacksonville$18K
- Anteneh FeyissaJacksonville$7K
- Brian CostellBoca Raton$469K
- Andrew LermanMiami$249K
- Alberto Pinzon ArdilaMiami$144K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- Mohamed NasserWeston$28K
- Miguel Melo-BicchiMiami$15K
- Claudio OsorioTampa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.